Latest Industry Projects

GSK Plans to Invest More Than £140 Million on UK Manufacturing Network

GSK Plans to Invest More Than £140 Million on UK Manufacturing Network

Introduction:

GSK plans to improve the efficiency and competitiveness of its manufacturing network with an investment of £140 Million.

Features:

These include both investments for respiratory and HIV medicines manufacturing in the UK and strategic reviews, including the sale of several products and a proposal to close a UK manufacturing site.

These medicines are produced at GSK sites in Ulverston, Cumbria, Verona in Italy and part of its Barnard Castle site. The Company has also decided to outsource some manufacturing activity at its Worthing site in the UK. GSK will continue to manufacture other antibiotics such as Augmentin and will continue to conduct research on new antibiotics.

The company has also decided not to proceed with a previously planned investment to build a biopharmaceutical facility in Ulverston as it no longer needs the additional capacity.

Specifications:

Name GSK
Location United Kingdom
Type Update Manufacturing Network
Estimated Cost £140 Million

 

Source: gsk.com 

Other Projects